drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (TCR-T cells)
drug_description
Autologous genetically engineered TCR-T cell product; patient T cells are transduced with a TCR recognizing the KRAS G12V neoepitope presented by HLA-A*11:01 to mediate MHC class I–restricted cytotoxic killing of KRAS G12V–mutant tumor cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
T-Lymphocytes, Genetically Modified
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a T-cell receptor specific for the KRAS G12V neoepitope presented by HLA-A*11:01. Upon peptide-HLA recognition, TCR signaling activates cytotoxic effector functions, leading to MHC class I-restricted killing of KRAS G12V–mutant tumor cells.
drug_name
YK0901
nct_id_drug_ref
NCT05933668